Lola.com

lola.com

Lola.com makes Agile Travel Management real by providing a super simple way to manage, book and report on business travel, saving employers and travelers time and money. Happy employee travel experiences within a policy can be set up in five minutes. Lola.com uses machine learning and 24/7 support to help travelers easily book trips, while empowering managers to create policies, view budgets and expenditures, and monitor their globetrotting team efficiently. Based in Boston, the company was founded in 2015 by Paul English, co-founder of the travel booking site KAYAK, and is led by CEO Mike Volpe, previously CMO at HubSpot.

C-Suite On Deck

Q&A with Jeanne Hopkins, CMO at Lola.com

Events

Related News

Business Insights

GNS HEALTHCARE AND ARVINAS ENTER INTO NEUROSCIENCE DRUG DISCOVERY COLLABORATION

GNS Healthcare | May 10, 2022

news image

GNS Healthcare, the leader in the use of "Virtual Patients", Causal AI and simulation technology for biopharmaceutical companies, today announced a collaboration with Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, to generate insights to help accelerate drug development for neurodegenerative diseases. Every year more than six million patients in the United States alone are diagnose...

Read More

Business Insights

COSÁN AND GENOMIND PARTNER TO HELP PREVENT ADVERSE PRESCRIPTION DRUG EVENTS FOR OLDER ADULTS

Cosán and Genomind | July 20, 2022

news image

Cosán, a provider of technology-driven preventative care services for older adults and the physicians that support them, and Genomind, a leading precision healthcare company, have partnered to fill an existing gap in aging adult care management by providing Cosán’s network of physicians with Genomind’s integrated precision medication management platform. The platform will provide insights that will help Cosán to achieve the best outcomes for their patient populat...

Read More

VIEWS AND ANALYSIS, PHARMACY MARKET

TELIX TO SUPPLY BAYER WITH ILLUCCIX® FOR GLOBAL PHASE III PROSTATE CANCER STUDY

prnewswire | May 08, 2023

news image

Telix Pharmaceuticals Limited announces that it has entered into an agreement with Bayer AG to supply Illuccix® kit for the preparation of gallium Ga 68 gozetotide injection)[1] for the Phase III ARASTEP study (ClinicalTrials.gov Identifier: NCT05794906). This global study is investigating the efficacy of Bayer's androgen receptor inhibitor (ARi) darolutamide plus androgen deprivation therapy (ADT) versus ADT alone in hormone-sensitive prostate cancer, in patients with high-risk bi...

Read More

Pharmacy Market

ARDELYX ANNOUNCES ACCEPTANCE OF NEW DRUG APPLICATION FOR TENAPANOR FOR HYPERPHOSPHATEMIA IN CHINA

Globenewswire | July 14, 2023

news image

Ardelyx, Inc. a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that a New Drug Application (NDA) for tenapanor has been accepted for review by China’s Center for Drug Evaluation of the National Medical Products Administration (NMPA) for the control of serum phosphorus in adult patients with chronic kidney disease on hemodialysis. This acceptance tri...

Read More
news image

Business Insights

GNS HEALTHCARE AND ARVINAS ENTER INTO NEUROSCIENCE DRUG DISCOVERY COLLABORATION

GNS Healthcare | May 10, 2022

GNS Healthcare, the leader in the use of "Virtual Patients", Causal AI and simulation technology for biopharmaceutical companies, today announced a collaboration with Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, to generate insights to help accelerate drug development for neurodegenerative diseases. Every year more than six million patients in the United States alone are diagnose...

Read More
news image

Business Insights

COSÁN AND GENOMIND PARTNER TO HELP PREVENT ADVERSE PRESCRIPTION DRUG EVENTS FOR OLDER ADULTS

Cosán and Genomind | July 20, 2022

Cosán, a provider of technology-driven preventative care services for older adults and the physicians that support them, and Genomind, a leading precision healthcare company, have partnered to fill an existing gap in aging adult care management by providing Cosán’s network of physicians with Genomind’s integrated precision medication management platform. The platform will provide insights that will help Cosán to achieve the best outcomes for their patient populat...

Read More
news image

VIEWS AND ANALYSIS, PHARMACY MARKET

TELIX TO SUPPLY BAYER WITH ILLUCCIX® FOR GLOBAL PHASE III PROSTATE CANCER STUDY

prnewswire | May 08, 2023

Telix Pharmaceuticals Limited announces that it has entered into an agreement with Bayer AG to supply Illuccix® kit for the preparation of gallium Ga 68 gozetotide injection)[1] for the Phase III ARASTEP study (ClinicalTrials.gov Identifier: NCT05794906). This global study is investigating the efficacy of Bayer's androgen receptor inhibitor (ARi) darolutamide plus androgen deprivation therapy (ADT) versus ADT alone in hormone-sensitive prostate cancer, in patients with high-risk bi...

Read More
news image

Pharmacy Market

ARDELYX ANNOUNCES ACCEPTANCE OF NEW DRUG APPLICATION FOR TENAPANOR FOR HYPERPHOSPHATEMIA IN CHINA

Globenewswire | July 14, 2023

Ardelyx, Inc. a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that a New Drug Application (NDA) for tenapanor has been accepted for review by China’s Center for Drug Evaluation of the National Medical Products Administration (NMPA) for the control of serum phosphorus in adult patients with chronic kidney disease on hemodialysis. This acceptance tri...

Read More